Ones To Watch News
Refine search
Pharmaceutical
Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. 5 March 2026
Pharmaceutical
French pharma Sanofi has agreed to license the experimental drug rovadicitinib from China’s Sino Biopharmaceutical, paying $135 million upfront for exclusive development and commercialization rights outside China. 5 March 2026
Biotechnology
Chinese cell therapy developer Lemang Biotech has raised nearly 200 million yuan ($28 million) in fresh financing to advance clinical development of its metabolism-enhanced CAR-T therapies and scale up manufacturing. 5 March 2026
Biotechnology
Shares of Hansa Biopharma rose nearly 7% to 32.98 kronor, after the Swedish company announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 5 March 2026
Biotechnology
US biotech Prolium Bioscience has announced its launch with a $50 million Series A financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. 4 March 2026
Biotechnology
US biotechnology company Candid Therapeutics will go public through a reverse merger with US rare disease drugmaker Rallybio, creating a Nasdaq-listed company focused on T-cell engager therapies for autoimmune diseases. 4 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Pharmaceutical
US clinical-stage biotech Latigo Biotherapeutics has appointed Neha Krishnamohan as chief financial officer and chief business officer, adding a finance executive with experience across biotech capital markets and corporate strategy as the company advances its non-opioid pain pipeline. 4 March 2026
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into an agreement to expand the drug discovery collaboration agreement with Canada’s Congruence Therapeutics for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology. 4 March 2026
Biotechnology
Belgium’s largest drugmaker UCB and Hong Kong based biotech Antengene have entered into an agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201 and access to its associated manufacturing technology in relation to ATG-201. Antengene’s shares rose almost 10% to HK$3.16 on the news. 4 March 2026
Pharmaceutical
Priovant Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. 3 March 2026
Biotechnology
UK-based 4basebio, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer. 3 March 2026
Biotechnology
US biotech Generate Biomedicines raised $400 million in its initial public offering, selling 25 million shares at $16 each, the midpoint of its range. It marks the largest biotech IPO so far this year and signals a tentative reopening of the sector’s capital markets. 2 March 2026
Biotechnology
Netherlands-based immunology company argenx has announced positive topline results from the Phase III ADAPT OCULUS study of Vyvgart (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG). 1 March 2026
Pharmaceutical
Switzerland’s Santhera Pharmaceuticals has announced that the Spanish Interministerial Commission on Prices of Medicines has proposed to include Agamree (vamorolone) in the pharmaceutical coverage of the National Health System, making it eligible for reimbursement. 27 February 2026
Pharmaceutical
Atrium Therapeutics launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. 27 February 2026
Biotechnology
German family-owned pharma major Boehringer Ingelheim and UK clinical stage biotech Sitryx Therapeutics announced that Boehringer has acquired an exclusive license for a pre-clinical, small molecule program from Sitryx. 27 February 2026
Pharmaceutical
UK-Hungarian virtual biology company Turbine has secured $25 million in a series B financing, broadened its platform beyond oncology and struck a new immunology collaboration with a top 10 pharma group. 26 February 2026
Biotechnology
Douglas Ingram has told Sarepta Therapeutics of his decision to retire as chief executive of the US genetic medicines company by the end of 2026 or upon the appointment of his replacement. 26 February 2026
Biotechnology
Privately-held US firm Abcuro has announced topline results from the Phase II/III MUSCLE study of ulviprubart (ABC008). 25 February 2026
Biotechnology
Privately-held UK based AMR Bio has announced its launch as a clinical phase biotechnology company focused on one of the most urgent public health challenges: preventing infection in an era where antibiotics are becoming less effective. 20 May 2026
Biotechnology
Canadian biotech InMed Pharmaceuticals is set to merge with privately held Mentari Therapeutics in an all-stock reverse merger that will create a Nasdaq-listed company focused on next-generation migraine prevention therapies. 20 May 2026
Pharmaceutical
Shares of US precision medicines company Relay Therapeutics were up 11.3% at $12.10 in pre-market activity today, after it announced highly encouraging initial clinical data from the Phase ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition. 19 May 2026
Biotechnology
US biotech Immunic today announced the appointment of Michael "Mike" W Bonney, a highly experienced biopharmaceutical executive and board leader, as chair of its board of directors, effective May 16, 2026. 19 May 2026
Biotechnology
Accro Bioscience, a Chinese biotech developing novel therapeutics that target molecular mechanisms of regulatory cell death for immune-mediated diseases, has announced the closing of its $50 million Series C financing. 19 May 2026
Pharmaceutical
US biotech Quince Therapeutics is abandoning its failed rare disease strategy and reinventing itself around pulmonary medicine after acquiring private company Orphai Therapeutics in a deal backed by up to $187 million in fresh financing. 19 May 2026
Pharmaceutical
US specialty pharma firm SERB Pharmaceuticals has entered to a deal with Hansa Biopharma for exclusive development and commercialization rights to Idefirix (imlifidase) in the European Union, UK, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA). 19 May 2026
Biotechnology
US biotech Regeneron Pharmaceutical announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis’ Helicon peptide platform, with a particular focus on Antibody-Helicon Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undruggable” targets. 19 May 2026
Biotechnology
Tarsier Pharma, an Israel-based Phase III biotech developing steroid-free therapies for ocular diseases, today announced terms for its initial public offering (IPO) plans to raise $45 million by offering 5 million shares at a price range of $8 to $10. 19 May 2026
Biotechnology
Sensorion, a French biotech specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, has announced the appointment of Fred Chereau as chief executive. 18 May 2026
Biotechnology
Privately-held US cell therapy company Orca Bio today announced the appointment of biopharma veteran Dr Bijan Nejadnik as chief medical officer (CMO). 18 May 2026
Biotechnology
Chinese biotech Akeso is pressing ahead with one of oncology’s most bruised targets, reporting mid-stage data suggesting its anti-CD47 antibody ligufalimab may improve survival outcomes in newly diagnosed acute myeloid leukemia patients unable to receive intensive chemotherapy. 18 May 2026
Pharmaceutical
California-based obesity-focused clinical-stage pharma Aardvark Therapeutics saw its shares tumble nearly 26% to $4.99, after it announced that the US Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the company’s previously announced voluntary pause. 15 May 2026
Biotechnology
CREATE Medicines has raised $122 million in a Series B financing round to support development of its in vivo CAR-T pipeline across autoimmune disease and oncology, as investor interest continues to grow around next-generation cell therapies. 15 May 2026
Biotechnology
China-headquartered Degron Therapeutics, a biotech advancing molecular glue degrader (MGD) medicines targeting previously undruggable or insufficiently drugged proteins, has announced the closing of a $40 million Series A extension. 14 May 2026
Pharmaceutical
US regulator the Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), giving BeOne Medicines its first regulatory clearance for the next-generation BCL-2 inhibitor. 14 May 2026
Biotechnology
Servier Ventures, the VC fund created by the French drugmaker, has selected Cytospire Therapeutics for its first investment. 13 May 2026
Biotechnology
Boehringer Ingelheim and US clinical-stage drug developer Immunitas Therapeutics have announced a global licensing agreement for a pre-clinical antibody program being developed for chronic inflammatory and autoimmune diseases. 13 May 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma announced a clinical trial collaboration and supply agreement with UK pharma major GSK to evaluate alnodesertib, Artios’ ATR inhibitor, in combination with risvutatug rezetecan (also referred to as Ris-Rez). 13 May 2026
Biotechnology
Privately-held Boston, USA, firm Cellular Intelligence has acquired global rights to Novo Nordisk's cell therapy program for Parkinson's disease. 12 May 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze